{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT03646123","nct_id":"NCT03646123","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03646123. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.","label":"Part A: A+AVD","type":"EXPERIMENTAL"},{"description":"Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.","label":"Part B: AN+AD","type":"EXPERIMENTAL"},{"description":"Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.","label":"Part C: AN+AD","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2024-08-23","type":"ACTUAL"},"conditions":["Hodgkin Lymphoma"],"enrollment":{"count":255,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"brentuximab vedotin","type":"DRUG"},{"name":"doxorubicin","type":"DRUG"},{"name":"vinblastine","type":"DRUG"},{"name":"dacarbazine","type":"DRUG"},{"name":"G-CSF","type":"DRUG"},{"name":"nivolumab","type":"DRUG"}],"last_update":"2025-08-28","lead_sponsor":"Seagen Inc.","official_title":"Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-11-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Febrile Neutropenia (FN) Rate (Part A)","timeFrame":"7.5 months"},{"measure":"Complete Response (CR) Rate at EOT (Parts B and C)","timeFrame":"7.8 months"}],"references":[{"citation":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary. Future Oncol. 2026 Jul;22(17):2027-2040. doi: 10.1080/14796694.2026.2693614. Epub 2026 Jul 6.","pmid":"42405616","type":"DERIVED"},{"citation":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026 Apr 9;147(15):1713-1722. doi: 10.1182/blood.2025030190.","pmid":"41460964","type":"DERIVED"},{"citation":"Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, Linhares Y, Gonzales P, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer H, Islas-Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw J, Ho L, Fanale MA, Guo W, Yasenchak CA. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16;145(3):290-299. doi: 10.1182/blood.2024024681.","pmid":"39622165","type":"DERIVED"}],"start_date":{"date":"2019-01-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03646123"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03646123"}